Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kagohashi, K.
Right arrow Articles by Sekizawa, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kagohashi, K.
Right arrow Articles by Sekizawa, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:960, 2003
© 2003 European Society for Medical Oncology

Letters to the Editor

Fatal hepatic failure due to gemcitabine and vinorelbine

K. Kagohashi1, Y. Funayama1, H. Satoh2 and K. Sekizawa2

1 Division of Respiratory Medicine, Tsukuba Gakuen Hospital 2 Institute of Clinical Medicine, University of Tsukuba, Tsukuba-city, Ibaraki, Japan

*E-mail: hirosato@md.tsukuba.ac.jp

The first 10% of the full text of this article appears below.

Gemcitabine and vinorelbine are indicated for the treatment of patients with inoperable non-small-cell lung carcinoma [1, 2]. We report fatal hepatic failure due to the combination of these two antitumor drugs in a patient . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?